Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The <i>BRAF</i> mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinoma

10 Jul 2006

Abstract excerpt

BACKGROUND: The activating BRAF(V600E) mutation is the most common genetic alteration reported in papillary thyroid carcinoma (PTC). While some reports suggest the BRAF(V600E) mutation is associated with factors predicting a poor prognosis and recurrence, this remains a controversial issue. AIM: To determine whether the presence of the BRAF(V600E) mutation is a prognostic indicator for clinical recurrence in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Thyroid and Parathyroid Surgery
Share to Thyroid Cancer Diagnosis and Treatment
Share to Thyroid Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16918957
DOI: 10.1111/j.1365-2265.2006.02605.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The <i>BRAF</i> mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinomaPMID 16918957Read ↗

Association Between <i>BRAF</i> V600E Mutation and Recurrence of Papillary Thyroid CancerSemantic proximity Read ↗

BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer.Semantic proximity Read ↗

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.Semantic proximity Read ↗

The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.Semantic proximity Read ↗

BRAFV600E Mutation is Associated with an Increased Risk of Papillary Thyroid Cancer Recurrence.Semantic proximity Read ↗

BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence.Semantic proximity Read ↗

BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.Semantic proximity Read ↗

BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity.Semantic proximity Read ↗

BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients.Semantic proximity Read ↗

Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.Semantic proximity Read ↗

BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.Semantic proximity Read ↗

BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrenceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.